Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I single-dose trial of ATI 9242 in volunteers

Trial Profile

Phase I single-dose trial of ATI 9242 in volunteers

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2011

At a glance

  • Drugs ATI 9242 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors ARYx Therapeutics
  • Most Recent Events

    • 02 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top